Merck Q1 earnings fall but beat expectations; 2026 guidance raised – Image for illustrative purposes only (Image credits: Pixabay)
Merck reported first-quarter results that exceeded analyst forecasts even as one-time acquisition costs pushed the company into a net loss. Worldwide sales reached $16.3 billion, a 5 percent increase from the same period a year earlier, with oncology products providing the main lift. The performance prompted the company to narrow and raise the midpoint of its full-year sales and earnings outlook, signaling confidence in its core business despite the near-term charges.
Core Product Momentum Offsets Acquisition Impact
Keytruda, the company’s flagship cancer immunotherapy, generated $8.0 billion in sales during the quarter, up 12 percent year over year. Demand remained robust across both metastatic and earlier-stage settings, while the newly launched subcutaneous version contributed $128 million in its first full quarter on the market. Winrevair, a treatment for a rare lung condition, added another bright spot with $525 million in revenue, an 88 percent jump from the prior year. These gains helped total revenue surpass Wall Street expectations of roughly $15.8 billion. At the same time, a substantial charge tied to the acquisition of Cidara Therapeutics produced a GAAP net loss of $4.24 billion, or $1.72 per share. On an adjusted basis that excludes the charge and other items, the company posted a loss of $1.28 per share, narrower than the $1.51 loss analysts had projected.
Updated Outlook Reflects Business Strength and Currency Tailwinds
Merck tightened its 2026 sales range to between $65.8 billion and $67.0 billion, raising the midpoint from its previous forecast. The company also lifted its adjusted earnings-per-share guidance to a range of $5.04 to $5.16, citing underlying operational momentum and a modest foreign-exchange benefit. The new outlook does not yet incorporate the expected close of a separate acquisition of Terns Pharmaceuticals, which is projected to add a one-time charge of about $5.8 billion, or roughly $2.35 per share, in the second quarter. Investors reacted to the mixed headline numbers with some caution, sending shares lower in early trading before they recovered modestly later in the session. The revised guidance, however, underscored management’s view that the underlying portfolio continues to deliver growth even as the company absorbs integration costs.
Stakeholders Weigh Short-Term Costs Against Longer-Term Pipeline Potential
Patients and physicians stand to benefit from continued expansion of Keytruda into new indications and the rollout of its subcutaneous formulation, which offers greater convenience. Healthcare systems and payers will monitor pricing and reimbursement dynamics as these products gain broader use. Shareholders, meanwhile, face near-term earnings pressure from acquisition accounting but gain visibility into a more focused revenue trajectory for the balance of the year. Analysts have noted that the company’s animal-health segment and recent product launches are also contributing incremental growth, helping diversify beyond the dominant oncology franchise. The narrowed guidance range suggests Merck sees limited downside risk in its base business assumptions through the end of 2026.
What Comes Next for Investors and the Broader Sector
Attention now turns to the closing of the Terns deal and any further regulatory updates on Keytruda label expansions. The company has already highlighted several clinical milestones achieved in the first quarter, including new approvals that could support additional revenue streams later in the year. For Merck employees and research partners, the results reinforce the priority placed on pipeline advancement even amid portfolio integration. The quarter illustrates how large pharmaceutical firms balance aggressive business development with the need to deliver consistent operational performance. As the year progresses, the market will assess whether the raised guidance holds and how the company manages the integration of its newest assets.
